Purpose To evaluate the feasibility and sensitivity of 18 F-DPA-714 for the study of microglial activation in the brain and spinal cord of transgenic SOD1 G93A mice using highresolution PET/CT and to evaluate the Iba1 and TSPO expression with immunohistochemistry. Methods Nine symptomatic SOD1 G93A mice (aged 117 ± 12.7 days, clinical score range 1 -4) and five WT SOD1 control mice (aged 108 ± 28.5 days) underwent 18 F-DPA-714 PET/CT. SUV ratios were calculated by normalizing the cerebellar (rCRB), brainstem (rBS), motor cortex (rMCX) and cervical spinal cord (rCSC) activities to that of the frontal association cortex. Two WT SOD1 and six symptomatic SOD1 G93A mice were studied by immunohistochemistry. Results In the symptomatic SOD1 G93A mice, rCRB, rBS and rCSC were increased as compared to the values in WT SOD1 mice, with a statistically significantly difference in rBS (2.340 ± 0.784 vs 1.576 ± 0.287, p = 0.014). Immunofluorescence studies showed that TSPO expression was increased in the trigeminal, facial, ambiguus and hypoglossal nuclei, as well as in the spinal cord, of symptomatic SOD1 G93A mice and was colocalized with increased Iba1 staining. Conclusion Increased 18 F-DPA-714 uptake can be detected with high-resolution PET/CT in the brainstem of transgenic SOD1 G93A mice, a region known to be a site of degeneration and increased microglial activation in amyotrophic lateral sclerosis, in agreement with increased TSPO expression in the brainstem nuclei shown by immunostaining. Therefore, 18 F-DPA-714 PET/CT might be a suitable tool to evaluate microglial activation in the SOD1 G93A mouse model.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons (MN) in the spinal cord, brainstem nuclei and motor cortex. Degeneration of MN results in muscle impairment, weakness and spasticity, and respiratory failure, leading to death within approximately 3 -5 years of symptom onset [1] [2] [3] [4] . Most cases of ALS are sporadic, but approximately 20 % of familial ALS and 5 % of apparently sporadic disease are associated with the gene encoding the enzyme Cu superoxide dismutase (SOD1) [2, 4] . The mechanisms underlying neurodegeneration in ALS are multifactorial, involving a complex interplay between molecular and genetic pathways [1, 4] . Neuroinflammation, and specifically activated microglia are neuropathological features of ALS and might play a role in MN degeneration and disease progression [5] [6] [7] [8] [9] . Postmortem studies in humans have shown astrocytosis and microgliosis in the motor cortex, the motor nuclei of the brainstem, the anterior horn of the spinal cord, and along the corticospinal tract [6, 9, 10] . Interestingly, the transgenic mouse overexpressing a mutant form of human SOD1, SOD1
G93A [11] , also displays ex vivo similar inflammatory responses to those seen in ALS patients, including activated microglia, astrogliosis and infiltrating lymphocytes accompanying MN injury in the spinal cord and brainstem [5, 6, 9, [12] [13] [14] . Moreover, in more advanced stages, inflammatory reactions are also detected in motor cortex [15, 16] and cerebellar nuclei [17] . Therefore, SOD1
G93A mice provide a useful and relevant tool for investigating neuroinflammation.
Glial activation can be assessed in vivo noninvasively using PET and selective radioligands for the 18-kDa translocator protein (TSPO), formerly known as the peripheral benzodiazepine receptor (PBR) [18] [19] [20] . Under physiological conditions, relatively low levels of TSPO are found in the central nervous system (CNS), but in response to neuroinflammation its expression increases markedly in activated glial cells [19] [20] [21] . In a pioneering study using PET and 11 C-PK11195, Turner et al. found increased binding in the motor cortex, pons, dorsolateral prefrontal cortex and thalamus in a group of ALS patients [22] . Using second-generation TSPO radioligands, characterized by higher specific binding, additional support has been provided for these findings [23, 24] . Post-mortem human studies have suggested that increased binding of both [
H](R)-PK11195 and [
3 H]DAA1106 overlap more prominently with CD68-labelled activated microglia than with GFAP-labelled astrocytes, at least in the motor cortex [25] . To our knowledge, no in vivo studies have demonstrated that increased TSPO expression in the brain and in the spinal cord of ALS might be related to microglial activation.
The use of animal models is of relevance for validation of PET TSPO radiotracers, in particular when combined with immunohistochemistry. This complementary approach may allow characterization of histopathological changes underlying in vivo imaging. Moreover, it could allow detection and monitoring of neuroinflammation from the presymptomatic stage and the evaluation of the effects of therapy. The aim of this proof-of-concept study was to investigate CNS neuroinflammation, in particular microglial activation, in symptomatic transgenic SOD1 G93A mice, both in vivo with PET/CT and 18 F-DPA-714, a promising radioligand for the study of TSPO sites [23, [26] [27] [28] [29] [30] recently validated in normal mice [31] , and ex vivo with immunohistological analysis. The results of this study highlight the feasibility and sensitivity of micro-PET and 18 F-DPA-714 in detecting increases in TSPO expression in the brain and in the spinal cord of the SOD1 G93A mouse model, and provide additional information on the relationships between TSPO expression and microglial activation underlying 18 F-DPA-714 PET changes.
Materials and methods

Animals and ethical statement
All experimental procedures complied with the European Communities Council directives (2010/63/EU) and national regulations (D.L. 116/92) and were performed in accordance with National Institutes of Health (NIH) recommendations. The present study was approved by the Animal and Care Committee of the University of Naples BFederico II^and by the Italian Ministry of Health (authorization number 1/2014-01-15). All efforts were made to minimize animal suffering and the number of animals necessary to produce reliable results. Mice were purchased from Jackson Laboratories (Bar Harbor, ME) via Charles River (Calco, LC, Italy) and were housed in group cages under standard conditions with free access to food and water. Experiments were carried out in a d u l t m a l e t r a n s g e n i c h e m i z y g o u s B 6 S J LTg[SOD1*G93A]1Gur/J mice (SOD1 G93A ; stock number 002726), expressing a high copy number (about 29) of the mutant human SOD1 allele with a Gly93Ala substitution [11, 32] , that are characterized by survival times of 128.9 ± 9.1 days. Transgenic hemizygous B6SJL-Tg(SOD1)2Gur/J (WT SOD1; stock number 002297), carrying the normal allele of the human SOD1 gene, served as controls for the SOD1 G93A strain, as it has been reported that WT SOD1 mice express the same level of SOD1 protein as SOD1 G93A mice and do not develop MN degeneration [11] .
Animal care, disease onset and progression analysis
To determine disease onset and progression, mice were monitored three times a week starting at 50 days of age using the clinical scoring system (CS) described by Solomon et al. [33] , with a scale from 0 to 5 as follows: 0 no evidence of disease, 1 shaking or splaying of the hind limbs when suspended by the tail, 1.5 weakness in one hind limb, 2 change in gait (toes curl under at least twice during walking, or any part of foot is dragging along cage bottom/table), 2.5 extreme weakness in one hind limb, 3 extreme weakness in both hind limbs, 3.5 functional paralysis in one hind limb, 4 functional paralysis in both hind limbs but can right themselves in less than 20 s after being placed on their side, 5 cannot right themselves to sternum within 20 s after being placed on their side (endpoint). SOD1 G93A mice with advanced symptoms of ALS (CS ≥2) had a palatable source of hydration and energy (GELDIET Energy; SAFE) placed on the bedding, and electrolyte balanced solutions were provided parenterally. Body weight and body condition score (BCS, scale 0 to 5) were evaluated three times a week, as described elsewhere [33] . Because of ethical considerations mice were euthanized after reaching a score of 4 according to the guidelines for preclinical testing and colony management [34] .
Radiochemical synthesis
All reagents and solvents were purchased from Sigma-Aldrich Corporation. Briefly, DPA- F were resynthesized in our laboratories according to previously described procedures [35] . 18 F was then trapped in a Chromafix PS-HCO3 cartridge, and after elution with 0.550 mL K 2 CO 3 (6 mg/mL) the 18 F-fluorine was collected in a vessel containing Kryptofix-222 dissolved in 1 mL CH 3 CN (K222 15 mg/mL). 18 F-DPA-714 was labelled with 18 F-fluoride (half-life 109.8 min) starting from the corresponding precursor using a tosyloxy-for-fluorine nucleophilic aliphatic substitution according to previously described procedures with slight modification [35, 36] . The specific activity at the end of synthesis and the radiochemical purity of 18 F-DPA-714 obtained within 90 min of radiosynthesis (HPLC purification and SepPak-based formulation included) were 300 GBq/μmol and N > 99 %, respectively.
In vivo imaging
Nine symptomatic SOD1 G93A mice aged from 98 to 137 days (mean ± SD 117 ± 12.75 days) with CS ranging from 1 to 4 (three CS 1, one CS 1.5, two CS 2, one CS 3, two CS 4; median CS 2) and five congenic controls WT SOD1 aged from 71 to 137 days (mean ± SD 108 ± 28.5 days) were studied. High-resolution PET/CT (GE Healthcare eXplore Vista; resolution 1.8 mm FWHM/200 μm, sensitivity 4.2 % ACS) were performed under inhalation anaesthesia (isoflurane 2 %, oxygen 2 L/min). Images were acquired in dynamic mode (frame sequence: 6 × 5 min) over 30 . PET frames acquired between 20 and 50 min were summed and used for data analysis.
Regions of interest (ROIs) were manually defined on summed axial PET images based on PET/CT fusion images using the mouse brain atlas of Paxinos and Franklin for guidance [37] . ROIs were placed on the cerebellum (6 mm 2 ), the brainstem (2.5 mm 2 ), the upper part of the cervical spinal cord (1.5 mm 2 ), the motor frontal cortex and the frontal association cortex (2 mm 2 ), over at least three consecutive slices using OsiriX 5.8.5 imaging software (Pixmeo, Bermex, Switzerland). ROIs on the thoracic and lumbar tracts of the spinal cord were excluded from analysis because these regions can be affected by partial volume effects due to the small size of these structures and the high 18 F uptake in the surrounding tissues, such as lung and kidneys [31] . For each brain region, 18 F-DPA-714 SUVs were calculated by pooling the ROIs defined over consecutive slices. SUV ratios were calculated by normalizing the cervical spinal cord (rCSC), cerebellar (rCRB), brainstem (rBS), and motor cortex (rMCX) activities to that of the frontal association cortex. This normalization was performed to reduce between-animal variability in radiotracer uptake. The frontal association cortex was used for normalization because this region is unaffected in SOD1 G93A mice as suggested by our in vivo and post-mortem data that showed no significant difference in SUVs between SOD1 G93A and WT SOD1 mice or post-mortem evidence of increased TSPO expression or microglial activation (see below).
Tissue processing and immunohistochemistry
Two control WT SOD1 and six symptomatic SOD1 G93A mice, one with a CS of 2, one a CS of 2.5 and four a CS of 4 (range of CS 2 -4, median 4) were studied using immunofluorescence analysis. All underwent PET from 1 to 9 days before euthanasia (mean ± SD 5 ± 3 days) except one SOD1 G93A mouse with a CS of 2. The mice were deeply anaesthetized (isoflurane 4 %, oxygen 2 L/min), and transcardially perfused with about 30 mL ice-cold phosphate-buffered saline (0.1 M PBS), followed by 60 mL of 4 % paraformaldehyde in saline solution. Their brain and spinal cord were then dissected out and postfixed overnight in 4 % paraformaldehyde at 4°C and cryoprotected in PBS containing 30 % sucrose for 48 h at 4°C. Brains and spinal cords were sectioned frozen on a sliding cryostat at 40 μm thickness, and free-floating sections were incubated with blocking solution (0.5 % milk, 10 % fetal bovine serum, 1 % bovine serum albumin) for 1.30 h [38] . Sections were then incubated overnight at 4°C with the following primary antibodies: rabbit monoclonal anti-PBR (1:500; Novus Biologicals) and mouse monoclonal anti-Iba1 (ionized calcium binding adapter molecule 1, 1:1000; Abcam).
Iba1 is a protein that in humans is encoded by the AIF1 gene. The AIF1 gene is located within a segment of the major histocompatibility complex class III region. It has been shown that this gene is highly expressed in testis, spleen, brain, lung and kidney [39] . Among brain cells, the Iba1 gene is specifically expressed in microglia. Upon activation of microglia due to inflammation, expression of Iba1 is upregulated allowing discrimination between physiological and activated microglia [40] . Iba1 is a 17-kDa EF hand protein that is specifically expressed in macrophages/microglia and is upregulated during activation of these cells [41] . Iba1 expression is upregulated in microglia following nerve injury, CNS ischaemia, and several other brain diseases [40] . Many studies have shown that Iba1 protein is expressed in microglia alone both in cultured brain cells and in the brain, respectively. In a mixed cell culture of embryonic rat brain, immunohistochemical analysis revealed that the localization of Iba1 protein is restricted to microglia, and it is not detectable in neurons, astroglia or oligodendrocytes [40] .
Subsequently, the sections were incubated with the corresponding fluorescence-labelled secondary antibodies (Alexa 488/Alexa 594-conjugated anti-mouse/anti-rabbit IgGs). Fluorescence was evaluated using a confocal microscope (Zeiss LSM 700). Single images were obtained with an optical thickness of 0.7 μm at a resolution of 1024 × 1024 and 40× magnification. In double-labelled sections, the pattern of immunoreactivity for both antigens was identical to that seen in single-stained material. Control double immunofluorescence staining entailed the replacement of the primary antisera with normal serum (data not shown). To minimize possible crossreactivity between IgGs in double immunolabelling experiments, the full complement of secondary antibodies was maintained, but the primary antisera were replaced with normal serum or only one primary antibody was applied (data not shown). In addition, the secondary antibodies were highly preadsorbed to the IgGs of numerous species. Tissue labelling without primary antibodies was also tested to exclude autofluorescence. No specific staining was observed under these control conditions, thus confirming the specificity of the immunosignals.
The following regions were studied: spinal cord, brainstem motor nuclei, cerebellum, motor cortex and prefrontal cortex. In one of the symptomatic SOD1 G93A mice with a CS of 4 only the motor cortex and spinal cord were available for immunohistochemistry. For the exact identification of the frontal association cortex and brainstem (oro)motor nuclei, the mouse brain atlas of Paxinos and Franklin [37] was used. The sections of each area were analysed within the following stereotaxic coordinates, expressed in millimetres: 3.20 -2.58 anterior to the bregma for the frontal association cortex, and 4.96 -5.34 posterior to the bregma for the trigeminal motor nucleus, 5.68 -6.48 for the facial nucleus, 6.70 -8.00 for the ambiguus nucleus, and 7.00 -7.12 for the hypoglossal nucleus. The spinal cord was divided into cervical (C1 -C4), thoracic (T8 -T11), and lumbar (L1 -L4) regions.
Statistical analysis
Descriptive statistics for body weight, BCS and CS were calculated in both SOD1
G93A and WT SOD mice and for survival in SOD1
G93A mice. 18 F-DPA-714 SUVs of the frontal association cortex and regional SUV ratios are presented as means ± SD. The clinical and 18 F-DPA-714 SUV data were analysed using the software package SPSS version 11 (SPSS, Chicago, IL). The nonparametric Mann-Whitney test was used to compare 18 F-DPA-714 SUVs of the frontal association cortex, and rCSC, rCRB, rBS and rMCX between SOD1 G93A and WT SOD mice. The sample size required to reach a 5 % level of significance with an 80 % power was estimated for the MannWhitney test [42] . The nonparametric Spearman's rank correlation coefficient was used to determine the degree of correlation between age and CS and rCSC, rCRB, rBS and rMCX in SOD1 G93A mice. The level of significance was set at p ≤ 0.05.
Results
Clinical score, body weight and body condition score
The SOD1 G93A mice became symptomatic from 95 days of age (mean ± SD 102.8 ± 7.04 days, range 95 -110 days). All SOD1 G93A mice that underwent in vivo PET studies showed a worsening in CS (ranging from score 1 to 4) and BCS (ranging from score 3 to 2) as the disease progressed. All WT SOD1 controls remained healthy (CS 0, BCS 3) at the endpoint ages of their matched SOD1 G93A mice. The average body weight of SOD1 G93A mice was significantly lower than that of WT SOD1 mice from the age of 14 weeks (mean ± SD 26.55 ± 2.49 g vs. 31.29 ± 1.84 g, respectively; p = 0.027) onwards, with the difference in body weight increasing with disease progression (Supplementary Fig. 1 ). Average survival time of the SOD1 G93A mice was 121 ± 12 days.
18
F-DPA-714 uptake in the CNS Visual assessment of PET images revealed that uptake of 18 F-DPA-714 in the brainstem and spinal cervical tract was clearly higher in symptomatic SOD1 G93A mice than in WT SOD1 mice, while the uptake in the anterior cerebral regions did not show any difference (Fig. 1) . The average SUV of the frontal association cortex in SOD1 G93A mice was not significantly different from that in the WT SOD mice (0.207 ± 0.090 and 0.225 ± 0.105, respectively; p = 0.787). SUV ratios measured in different CNS regions of the SOD1 G93A and WT SOD1 mice are summarized as means ± SD in Table 1 and Fig. 2 . The mean rBS values were significantly higher in symptomatic SOD1 G93A mice than in WT SOD1 controls (p = 0.014). The mean rCSC values were also higher by 59 % in symptomatic SOD1 G93A mice than in WT SOD1 controls, but this difference was not significant (p = 0.053). There were no significant differences in rCRB and rMCX values between symptomatic SOD1 G93A mice and WT SOD1 controls (rCRB p = 0.162, rMCX p = 0.162). In symptomatic SOD1 G93A mice, CS showed a statistically significant correlation with age in days (R = 0.786, p ≤ 0.05), whereas there was no significant correlation between CS and 18 F-DPA-714 SUV ratios.
Immunohistochemistry
The numbers of Iba1-positive cells were higher in the trigeminal, facial, ambiguus and hypoglossal nuclei of the SOD1 G93A mice with a CS of 4 than in these regions of the WT SOD1 controls (Fig. 3) , and showed differences in morphology such as a larger cell body and shorter cellular processes. In the facial nucleus in particular (Fig. 4) , Iba1-positive cells showed a dramatic difference in morphology, mainly characterized by enlarged shape and shorter cellular processes. Moreover, TSPO expression was clearly higher in brainstem nuclei, and double immunohistochemical analysis revealed that it was colocalized with Iba1-positive cells, mainly with large-body cells. Iba1 and TSPO expression was also higher in SOD1 G93A mice with a CS of 2 -2.5 than in WT SOD1 controls, although the difference was not as great as in SOD1 G93A mice with a CS of 4. Similarly, TSPO expression was colocalized with Iba1 immunoreactivity in most nuclei. In the trigeminal nucleus, the greater number of Iba1-positive cells was quite marked, while the difference in TSPO expression was less marked compared with mice with a CS of 4. Higher expression was found in the cerebellum and in the motor cortex of two different mice with a CS of 4. However, Iba1 and TSPO expression in the frontal association cortex was not higher in SOD1 G93A mice than in WT SOD1 controls ( Supplementary Fig. 2 ). In the cervical and thoracic spinal cord (Fig. 5a, b) of SOD1 G93A mice with a CS of 4, Iba1 expression was higher than in these regions of WT SOD1 controls. Moreover, TSPO expression was high in SOD1 G93A mice with a CS of 4, but was very low in those with a CS of 2.5. Finally, Iba1 expression in the lumbar spinal cord (Fig. 5c ) was high in SOD1 G93A mice regardless of their CS. Indeed, it was similar in SOD1 G93A mice with CS of 2.5 and in those with a CS of 4. Conversely, TSPO expression was lower in SOD1 G93A mice with a CS of 2.5 than in those with a CS of 4.
Discussion
The results of this proof of concept study suggest that a significant increase in 18 F-DPA-714 uptake can be measured with high-resolution PET/CT in the brainstem of symptomatic SOD1 G93A mice, a model of ALS. Moreover, immunostaining showed that TSPO expression was increased in the brainstem nuclei and was colocalized with Iba1 immunoreactivity, suggesting that increased microglial activation might underlie at least in part the increased brainstem 18 F-DPA-714 uptake. In contrast, the uptake of 18 F-DPA-714 and TSPO and Iba1 expression were not significantly increased in transgenic mice over-expressing the nonmutated wild-type human SOD1. To our knowledge, this is the first study in which PET and TSPO radiotracer have been applied to the SOD1 G93A mouse model of ALS and were combined with immunohistochemistry for the evaluation of TSPO expression and microglial activation.
There is a growing body of evidence from post-mortem [13, 14, 43] and in vivo MRI studies combined with histopathology [44] [45] [46] [47] [48] suggesting that selective brainstem nuclei are the site of degenerative changes and/or strong inflammatory reaction in SOD1-ALS transgenic mice. In particular, the trigeminal, facial and ambiguus nuclei have been found to be consistently affected, while the hypoglossal nucleus has been found to be altered in some studies [14, [46] [47] [48] but uninvolved in others [43, 44] . The reasons why MN are particularly susceptible to injury in the presence of mutations that affect ubiquitously distributed proteins, such as SOD1, are not completely understood [1] . Putative mechanisms include a toxic gain in function of the SOD1 enzyme, conformational instability and misfolding of the SOD1 peptide [1, 4] . Interestingly, brainstem nuclei more severely affected in advanced stage SOD1 G93A mice have higher levels of human mutant SOD1 accumulation in this preclinical model, possibly modulating differential formation of protein aggregates associated with MN degeneration [49, 50] . Both astrogliosis and microgliosis appear simultaneously with the degenerative changes either before or after symptoms and increase substantially with time [48] . The earliest changes are found at 60 days for astrocytes and 80 days for microglia [48] . Interestingly, in this latter report the authors suggested that astrocyte and microglia activation, and not only vacuolization, might have contributed to T2-weighted changes found in motor brainstem nuclei of SOD1 G93A mice, since no detectable changes in T1 signal intensity were observed. These changes seen on MRI cannot, however, provide specific information on neuroinflammatory cellular alterations.
The results of our study revealed that brainstem gliosis could be evaluated directly in vivo using PET and 18 F-DPA-714 in a mouse model of ALS. Although specific brainstem nuclei cannot be identified with PET, due to its lower spatial F-DPA-714 SUV ratios (mean ± SD) in relation to the frontal association cortex in the cervical spinal cord (rCSC), cerebellum (rCRB), brainstem (rBS) and motor cortex (rMCX) in WT SOD1 control mice and symptomatic SOD1
G93A mice. The brainstem shows significantly higher uptake of 18 
F-DPA-714 in symptomatic SOD1
G93A mice (*p < 0.02) G93A mice. Our study showed for the first time that increased TSPO expression can also be found in the same brainstem nuclei and colocalized with Iba1-activated microglia with large cell bodies and short cellular processes. These changes were particularly marked in the facial and ambiguus nuclei, and in more severely clinically affected mice (CS of 4), while they were not found in WT SOD1 mice of similar age. These findings are in line with the sustained and progressive increase of microglial activation previously reported in brainstem nuclei in symptomatic SOD1 G93A mice [48] . Moreover, our findings are in agreement with those of previous studies in humans showing an increased [ 11 C](R)-PK11195 PET signal in the pons of ALS patients [22] , and with those of a more recent study showing increased PBR28 uptake in the brainstem of individuals with bulbar-onset ALS [24] . This latter finding (observed only in three patients) deserves further investigation and suggests that TSPO expression might be related to the clinical phenotype of ALS. Interestingly, our data are also in line with a recent 18 F-FDG PET study [51] showing increased relative glucose metabolism in the midbrain of patients with ALS, possibly related to gliosis. The SOD1 G93A mouse model has been used extensively to study the degeneration of the spinal cord; nonetheless, previous evidence and our results suggest that the occurrence of brainstem degeneration is reminiscent of ALS and that this model might be of relevance for the study of bulbar-onset ALS phenotype [13] .
We did not find significant increases in 18 F-DPA-714 binding in the cerebellum and motor cortex. Previous studies have indicated that, as in humans, SOD1-ALS transgenic mice also show more widespread degenerative and/or inflammatory changes involving other brain regions than the spinal cord and brainstem including the cerebellum [17, 44] , and the motor cortex [15, 16, 52] . Zang et al. [44] found decreased T2 signal intensity in the cerebellum, suggesting the presence of atrophy, while degeneration and/or inflammation was found in the motor cortex but mainly during late stages [52] . Using a combination of anatomic, cellular, transgenic labelling, and newly available neuronal subtype-specific molecular analyses, Ozdinler et al. [16] found that degeneration of corticospinal MN occurs from the early presymptomatic stages in hSOD1G93A mice, while activated microglia and astrocytes mainly occur during late stages of disease and are not restricted to the motor cortex. Thus, our findings are in line with mild changes reported in these regions of SOD1 G93A mice. Detection of these changes presumably lies beyond the resolution of the PET technique. Interestingly, increased Iba1 and TSPO expression were found in the motor cortex of one symptomatic SOD1 G93A mouse and in the cerebellum of another mouse, both with a of CS of 4 (data not shown). Further studies are required to address this interesting issue.
Although average 18 F-DPA-714 binding in the cervical tract of the spinal cord was 59 % higher in our symptomatic SOD1 G93A mice than in WT SOD1 mice, the difference was not significant. This suggests a certain variability in the individual binding and/or low accuracy of in vivo PET measurement in this region probably due partial volume effects and/or low number of animals. Given the relatively small size of some of the sampled structures, as compared with the resolution of the scanner, the partial volume effect may have contributed to scattering of the data, so that possible significant differences could not be detected, especially in the cervical spinal cord. On the other hand, the significant increases in the brainstem that we found can hardly be explained by such a phenomenon. Given the current lack of a general consensus on a satisfactory partial volume correction method for smallanimal PET [53] , especially when spill-in from Bhotê xtracerebral structures is present, we did not attempt to include this processing step in our analysis. In particular for 18 F-DPA-714, given the high uptake of tracer in some extracerebral structures (e.g. Harderian and salivary glands, and nasopharyngeal lymphoid tissue [54] and paravertebral structures (e.g. nuchal muscles), partial volume effect correction also needs to model these structures to be fully effective [55] .
In contrast, our immunohistological results clearly showed increased TSPO expression in the cervical, thoracic and lumbar spinal tracts, that colocalized with Iba1 immunoreactivity, with a trend for stronger expression in the cervical and lumbar tracts and, similar to that in the brainstem, in mice with higher CS. These results are in accordance with previous postmortem findings of increased microglial reactivity in lumbar and/or the cervical/thoracic spinal cord of mutant SOD1 G93A mice [14, 56, 57] and transgenic hmSOD1G93A rats [58] .
Moreover, that study also demonstrated increased TSPO expression in the spinal cord of symptomatic SOD1 G93A mice. This suggests that PET and TSPO radioligands could be used for the study of spinal cord microglial activation in ALS patients.
We did not find any significant correlation between the CS and regional 18 F-DPA-714 binding, in particular in the brainstem of symptomatic SOD1 G93A mice. To our knowledge, no study has evaluated the correlation between clinical severity and microglial activation in the brainstem of SOD1 G93A mice. In a previous study, a highly significant correlation was found in SOD1 G93A mice between increased T2 values in the brainstem nuclei and behavioural deficit (exploratory behaviour, locomotor activity) [45] . Previous PET studies in ALS patients have shown a significant correlation between upper motor neuron (UMN) score and increased TSPO radiotracer binding in the motor cortex [22] [23] [24] , but not with disease duration. The small number of animals and the lack of more appropriate clinical evaluation specifically focused on Bbulbar^signs might in part explain our results. Future studies are required to specifically address this issue.
Overall the results of our study suggest that increased 18 F-DPA-714 binding measured with PET in the brainstem of symptomatic SOD1 G93A mice is due to increased TSPO expression in activated microglia, at least at later clinical stages, and further emphasize the valuable role of TSPO radiotracers as in vivo markers of microglia activation associated with neurodegenerative diseases such as ALS. Microglial cell activation has been implicated in the pathogenesis of several neurodegenerative conditions, including ALS [5] [6] [7] 59 ]. Neuroinflammation, and in particular microglial activation, may mediate both beneficial and harmful effects within the diseased area of the CNS in ALS [6, 7] . Thus, a better understanding of glial-neuronal interactions might be useful in future development of more efficient therapies. We cannot exclude the possibility that astrocyte activation might also underlie increased TSPO expression and 18 F-DPA-714 uptake found in our mice, since strong GFAP immunostaining has also been reported in the brainstem nuclei and/or spinal cord of transgenic SOD1 G93A mice [9, 13, 14, 56, 57] . The evaluation of astroglial activation was not the aim of this study. However, preliminary results (data not shown) in one symptomatic SOD1 G93A mouse with a CS of 4 revealed increased GFAP immunoreactivity in the brainstem nuclei and spinal cord without clear colocalization with TSPO immunolabelling. Our data are in line with post-mortem findings showing a correlation between increased binding of two TSPO PET radiotracers (H3-PK11195 and H3-DAA 1106) and cd11 immunostaining in the primary motor cortex of patients with ALS [25] , and with previous reports suggesting that TSPO is highly expressed in activated microglia, and to a lesser extent in reactive astrocytes in other CNS disorders [19, 20] . Further studies, aimed at addressing the specific contribution of astrocyte activation to the increased TSPO expression in the brainstem nuclei and spinal cord are needed to resolve this issue.
The main limitation of this proof of concept study was the relatively small number of mice. Thus, caution is required in the interpretation of the results. Estimated sample sizes per group ranged from 9 for the cervical spinal cord to 18 for the cerebellum and motor cortex [42] . Further studies in a larger group of animals are needed to assess the sensitivity of 18 F-DPA-714 PET in detecting changes occurring in the brainstem and in other CNS regions of SOD1 G93A mice at different stages of disease, including the presymptomatic stage, and to evaluate whether these changes have clinical relevance.
We failed to measure with PET significant in vivo changes in 18 F-DPA-714 uptake in the spinal cord. This suggests that PET with 18 F-DPA-714 is not sensitive enough to detect microglial activation and increased TSPO expression in mice, at least at the cervical level. Future studies should assess whether micro-PET with higher resolution, or the development of adequate methods for PVE correction might improve the sensitivity and accuracy. Finally, in this study we did not attempt to quantify the immunohistochemical data, thus excluding the possibility of carrying out a quantitative correlation analysis with 18 F-DPA-714 uptake, as only visual evaluation was performed. Future studies are required to address this specific issue.
In conclusion, despite the limitations mentioned above, our study suggests that micro-PET and 18 F-DPA-714 might be a useful tool for the study of microglial activation in the SOD1 G93A mouse model. Future studies are required to evaluate the sensitivity of this technique for studying disease progression and the effects of innovative therapies. In this respect, it should be stressed that in SOD1 G93A mice a different clinical phenotype (e.g. disease onset and progression) could be related to a different genetic background [60] . In a combined MRI and histological study increased T2 values in cranial motor nuclei, associated with significant tissue vacuolization, were more marked in SOD1 G93A mice with a C57BL/6 J genetic background than in those with a 129S2/SvHsd genetic background, despite the latter exhibiting faster disease progression [60] . These observations suggest that the prognostic value of an in vivo marker should be tested and validated in different animal models. Although neuroinflammatory markers were not evaluated in the study by Caron et al. [60] , further studies are required to characterize microglial activation and 18 F-DPA-714 uptake in other animal models with different disease progression rates and severity to enable monitoring of the effects of therapies or the development of new therapeutic strategies.
Nevertheless, the results of this study strengthen the high relevance of combined preclinical PET and immunohistochemistry studies for the cellular characterization of the PET signal in vivo. 
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